Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib, everolimus, and exemestane in HR+/HER2- metastatic breast cancer
NCT02871791Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2016
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Dana-Farber Cancer Institute. Started Aug 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02871791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871791.